← Leaderboards
Jason J. Gill
Texas A&M Agrilife Research
$1,322,754
Attributed
$2,237,883
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $454.7K · FY2015–20$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,237,883 · 4
By mechanism
R33$1,352,836 · 1
R21$877,547 · 2
R13$7,500 · 1
Top collaborators
- Thomas Walsh5 shared
- Elizabeth Martin Kutter1 shared
Most similar at Texas A&M Agrilife Research
Same institution · by research overlap
- Junjie Zhang$4,460,630
- Lanying Zeng$1,948,878
- Thomas Walsh$911,379
Others in their field
Top investigators on “Bacteria”
- James E. Gern · University Of Wisconsin-Madison$138,333,846
- Ian A Wilson · Scripps Research Institute, The$90,122,969
- Vance G Fowler · Duke University$85,101,521
- Henry F Chambers · Duke University$84,838,080
- Timothy Henkel · Venatorx Pharmaceuticals, Inc.$48,397,895
- David Alland · Rutgers Biomedical And Health Sciences$47,292,355
Research focus
BacteriaBaseOrganismPathogenMedicalVirusLyticBacteriophagesAntibioticsAntibiotic ResistanceCommunitiesAnimal ModelNational Institute Of Allergy And Infectious DiseaseLeadAntimicrobial DrugBiologicalAntimicrobialBacterial ResistanceDrug ResistanceBacterial InfectionsCombatInfectionEffective TherapyLibraries
Grant awards (8)
Development of therapeutic bacteriophages against carbapenemase-resistant Klebsiella pneumoniae$448,294
R33 · FY2020 · AI · contact PI
Development of therapeutic bacteriophages against carbapenemase-resistant Klebsiella pneumoniae$449,794
R33 · FY2019 · AI · contact PI
Development of therapeutic bacteriophages against carbapenemase-resistant Klebsiella pneumoniae$454,748
R33 · FY2018 · AI · contact PI
Development of therapeutic bacteriophages against carbapenemase-resistant Klebsiella pneumoniae$235,888
R21 · FY2017 · AI · contact PI
22nd Evergreen International Phage Biology Meeting$7,500
R13 · FY2017 · AI
Development of therapeutic bacteriophages against carbapenemase-resistant Klebsiella pneumoniae$234,034
R21 · FY2016 · AI · contact PI
The Twort-like bacteriophages of Staphylococcus aureus: paradigm phages for novel therapeutics$185,625
R21 · FY2016 · AI · contact PI
The Twort-like bacteriophages of Staphylococcus aureus: paradigm phages for novel therapeutics$222,000
R21 · FY2015 · AI · contact PI